Treatment of disseminated superficial actinic porokeratosis with oral alitretinoin

Park, B J; Oh, Eui Hyun; Kim, J E; Ko, Joo Yeon; Ro, Young Suck

doi:10.1111/jdv.14354

Cited by 11 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The initial dose was 0.3 mg/kg daily and was tapered to 0.3 mg/kg every other day after achieving complete remission (4 weeks), then continued for 3 months, and for the next 14 months, further reduced to twice a week with good control of the disease. Alitretinoin was reported to be effective in two patients (10 mg daily; 4-and 7-month treatment) and well tolerated [149]. The effectiveness of oral etretinate (0.75-1 mg/kg or 50-100 mg daily; 8-week treatment) was good to excellent in three cases [150][151][152], moderate in two cases [151] and none in one (75 mg/day; 3 weeks) [153].…”

Section: Treatmentmentioning

confidence: 95%

Porokeratoses—A Comprehensive Review on the Genetics and Metabolomics, Imaging Methods and Management of Common Clinical Variants

Pietkiewicz,

Korecka,

Salwowska

et al. 2023

Metabolites

View full text Add to dashboard Cite

Porokeratosis is a heterogeneous group of keratinising disorders characterised by the presence of particular microscopic structural changes, namely the presence of the cornoid lamella. This structure develops as a consequence of a defective isoprenoid pathway, critical for cholesterol synthesis. Commonly recognised variants include disseminated superficial actinic porokeratosis, disseminated superficial porokeratosis, porokeratosis of Mibelli, palmoplantar porokeratosis (including porokeratosis palmaris et plantaris disseminata and punctate porokeratosis), linear porokeratosis, verrucous porokeratosis (also known as genitogluteal porokeratosis), follicular porokeratosis and porokeratoma. Apart from the clinical presentation and epidemiology of each variant listed, this review aims at providing up-to-date information on the precise genetic background, introduces imaging methods facilitating the diagnosis (conventional and ultraviolet-induced fluorescence dermatoscopy, reflectance confocal microscopy and pathology), discusses their oncogenic potential and reviews the literature data on the efficacy of the treatment used, including the drugs directly targeting the isoprenoid–mevalonate pathway.

show abstract

Section: Treatmentmentioning

confidence: 95%

Porokeratoses—A Comprehensive Review on the Genetics and Metabolomics, Imaging Methods and Management of Common Clinical Variants

Pietkiewicz,

Korecka,

Salwowska

et al. 2023

Metabolites

View full text Add to dashboard Cite

show abstract

“…Two DSAP patients responded well to oral alitretinoin 10-20 mg daily for 4-7 months leading to a significant reduction of the size, number, and itching of their PKs. 27 However, the potential side effects of long-term regular use of retinoids, such as dryness, lipid abnormalities, hepatotoxicity, and reproductive toxicity should always be taken into consideration.…”

Section: Conventional Therapiesmentioning

confidence: 99%

Conventional and Novel Treatment Strategies for Porokeratoses: A Narrative Review

La,

Zhu,

Mueller

2024

J Deutsche Derma Gesell

View full text Add to dashboard Cite

SummaryPorokeratoses are a heterogenous group of autoinflammatory keratinization disorders all characterized by the presence of a cornoid lamella. In addition to gene mutations affecting the mevalonate pathway, environmental factors such as UV radiation, immunosuppression, trauma, and infection are also thought to contribute to porokeratoses. To date, there are no management guidelines or levels of evidence for commonly used pharmacologic and non‐pharmacologic treatment options for porokeratoses. Conventional treatment strategies encompass topical and systemic drugs (e.g., salicylic acid, topical glucocorticoids, and retinoids), phototherapy, laser, and surgical interventions. Better insights into the pathogenesis of porokeratoses have paved the way for the development of novel therapeutic approaches, such as topical statins or the use of monoclonal antibodies. This narrative review aims to summarize both conventional and novel treatment options, including their level of evidence, advantages, and disadvantages.

show abstract

“…Oral verabreichte Retinoide können für Patienten mit PK geeignet sein, die ausgedehnte Hautläsionen haben oder auf topische Behandlungen nicht ansprechen. Zwei DSAP‐Patienten sprachen gut auf die orale Einnahme von Alitretinoin 10–20 mg täglich über einen Zeitraum von 4–7 Monaten an, was zu signifikanter Reduktion der Größe, der Zahl und der Pruritus‐Episoden ihrer PKs führte 27 . Allerdings sollten die potenziellen Nebenwirkungen einer regelmäßigen Langzeiteinnahme von Retinoiden, wie Trockenheit, Störungen im Fettstoffwechsel, Hepatotoxizität und Reproduktionstoxizität, stets berücksichtigt werden.…”

Section: Konventionelle Therapienunclassified

Konventionelle und neue Behandlungsstrategien bei Porokeratosen: Eine narrative Übersicht

La,

Zhu,

Mueller

2024

J Deutsche Derma Gesell

View full text Add to dashboard Cite

ZusammenfassungPorokeratosen sind eine heterogene Gruppe autoinflammatorischer Keratinisierungsstörungen, die durch kornoide Lamellen gekennzeichnet sind. Neben Genmutationen, die sich auf den Mevalonat‐Stoffwechselweg auswirken, werden auch Umweltfaktoren wie UV‐Strahlung, Immunsuppression, Traumata und Infektionen für die Entstehung von Porokeratosen verantwortlich gemacht. Bislang gibt es keine Behandlungsrichtlinien oder Evidenzgrade für die gängigen pharmakologischen und nicht‐pharmakologischen Behandlungsoptionen bei Porokeratosen. Zu den konventionellen Behandlungen zählen topische und systemische Medikamente wie Salicylsäure, topische Glucocorticoide und Retinoide, Phototherapie, Laser und chirurgische Verfahren. Bessere Erkenntnisse über die Pathogenese von Porokeratosen haben die Entwicklung neuartiger therapeutischer Ansätze ermöglicht, etwa topische Statine oder monoklonale Antikörper. In dieser narrativen Übersichtsarbeit werden sowohl die herkömmlichen als auch neuen Behandlungsmöglichkeiten einschließlich ihres Evidenzgrads sowie ihrer Vor‐ und Nachteile zusammengefasst.

show abstract

Treatment of disseminated superficial actinic porokeratosis with oral alitretinoin

Cited by 11 publications

References 10 publications

Porokeratoses—A Comprehensive Review on the Genetics and Metabolomics, Imaging Methods and Management of Common Clinical Variants

Porokeratoses—A Comprehensive Review on the Genetics and Metabolomics, Imaging Methods and Management of Common Clinical Variants

Conventional and Novel Treatment Strategies for Porokeratoses: A Narrative Review

Konventionelle und neue Behandlungsstrategien bei Porokeratosen: Eine narrative Übersicht

Contact Info

Product

Resources

About